UNSPSC 51314103: Thonzylamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H22N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R79646H5Z8, chemically known as pyrimidine, 2-((2-(dimethylamino)ethyl)(p-methoxybenzyl)amino)- but generally known as thonzylamine, which bears US NIH Compound Identifier 5457. European Medicines Agency schedules Thonzylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10988MIG. The term THONZYLAMINE is an International Non-Proprietary Name.

UNSPSC 51314103 Thonzylamine is a Commodity code that sits at the bottom of the pharmaceutical products taxonomy, but recent state and local procurement activity under this code does not center on thonzylamine itself. Instead, issuing bodies are soliciting pharmaceuticals and related health products across a broader range — naloxone, generic multi-source drugs, and over-the-counter items — often bundled into cooperative purchasing agreements or specialized health initiatives. State and local buyers include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The work involves procuring finished pharmaceutical products for distribution to community health facilities, emergency response programs, and state employee and retiree health plans, with vendors required to meet cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized wholesalers, and provide detailed product information including National Drug Codes and pricing structures.

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota alliance extending procurement scope to Oregon and other participating jurisdictions. Representative recent solicitations include an Seminole County IFB (IFB60459723LAS) posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; a Texas Health and Human Services Commission Request for Information (HHS0017013) posted April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and an MMCAP Request for Proposal (S1070000015802) issued January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline and July 1, 2026, effective date for awarded contracts. The MMCAP procurement weights price competitiveness at 75 percent and requires vendors to maintain authorized wholesaler relationships, cGMP certification, and insurance coverage including $5,000,000 commercial general liability per occurrence.